Overall Survival Clinical Trial
Official title:
Guangdong Association of Clinical Trials
ICAN was a non-interventional study to explore the EGFR gene mutation status, clinical
outcome and recurrent risk factors in early stage Chinese NSCLC with adenocarcinoma histology
after complete resection (NIS-OCN-DUM-2009/1). The study had enrolled 571 patients from Apr.
2010 to Dec. 2010 in 24 sites located in the mainland of China. The study had completed and
major results showed that EGFR mutation rate was 55.1% and 3-year DFS rate was 61.7% in early
stage Chinese NSCLC with adenocarcinoma histology after complete resection. Postoperative
pathologic stage, gender, surgical and resection types had a statistically significant
association with 3-year DFS.
This study is ICAN extension study with the purpose to collect the overall survival data from
previous ICAN study. Approximately 571 patients who participated in ICAN study will be
enrolled.
Primary objective
- To observe the overall survival of early stage NSCLC with adenocarcinoma histology after
complete resection that had enrolled in I CAN study.
Secondary objectives
- To observe the updated DFS of early stage NSCLC with adenocarcinoma histology after
complete resection that had enrolled in I CAN study;
- To observe the treatment pattern after tumor recurrence of early stage NSCLC with
adenocarcinoma histology after complete resection that had enrolled in I CAN study in
real-world setting;
- To explore the risk factors of OS for early stage NSCLC with adenocarcinoma histology
after complete resection that had enrolled in I CAN study in real-world setting, such as
EGFR mutation status, gender, smoking history, treatment pattern after recurrence, etc.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04025840 -
Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery
|
Phase 4 | |
| Completed |
NCT04111926 -
Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery
|
Phase 4 | |
| Recruiting |
NCT04101760 -
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03342300 -
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03910140 -
TILA-TACE in Treatment of Hepatocellular Carcinoma
|
N/A | |
| Completed |
NCT03923400 -
Jejunoileal vs Gastric GIST in the Era of Imatinib.
|
||
| Withdrawn |
NCT02201381 -
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
|
Phase 3 | |
| Recruiting |
NCT05392257 -
Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial
|
Phase 2 | |
| Recruiting |
NCT05310357 -
Chromosomal Instability in Ovarian Cancer
|
||
| Recruiting |
NCT05310370 -
HRD and Resistance to PAPPi in EOC Patients
|
||
| Recruiting |
NCT05310305 -
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
|
||
| Active, not recruiting |
NCT04245644 -
Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study
|
||
| Recruiting |
NCT04245410 -
Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma
|
||
| Completed |
NCT02980185 -
Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer
|
N/A | |
| Recruiting |
NCT03967457 -
Comprehensive Study on the Quality of Life in Cervical Cancer Patients
|
||
| Recruiting |
NCT04050787 -
Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer
|
N/A | |
| Recruiting |
NCT03892577 -
Real-world Study for Patients With Advanced Hepatobiliary Tumors
|
||
| Completed |
NCT03726021 -
Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT02942238 -
Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC)
|
N/A | |
| Not yet recruiting |
NCT01236989 -
Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC
|
N/A |